Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse

Preassociation of IL-15 with IL-15R -IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action

(2014) S. Dubois et al.   JOURNAL OF IMMUNOLOGY

Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency

(2013) Marie Vincent et al.   INTERNATIONAL JOURNAL OF CANCER

Recombinant Human IL-15 Trans-Presentation by B Leukemic Cells from Chronic Lymphocytic Leukemia Induces Autologous NK Cell Proliferation Leading to Improved Anti-CD20 Immunotherapy

(2013) E. Laprevotte et al.   JOURNAL OF IMMUNOLOGY

The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential

(2013) Béatrice Clémenceau et al.   mAbs

Antibody–cytokine fusion proteins

(2012) Roland E. Kontermann   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Properties of mouse and human IgG receptors and their contribution to disease models

(2012) P. Bruhns   BLOOD

Immunocytokines: a novel class of potent armed antibodies

(2012) Nadine Pasche et al.   DRUG DISCOVERY TODAY

Rituximab resistance

(2011) Andrew R. Rezvani et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression

(2011) Esther Moga et al.   EXPERIMENTAL HEMATOLOGY

Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma

(2010) Lan Wu et al.   CANCER LETTERS

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

(2010) Gregory L. Moore et al.   mAbs

Macrophage- and Dendritic-Cell-Derived Interleukin-15 Receptor Alpha Supports Homeostasis of Distinct CD8+ T Cell Subsets

(2009) Erwan Mortier et al.   IMMUNITY

High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor   fusion protein, in metastatic melanoma and colorectal cancer

(2009) A. Bessard et al.   MOLECULAR CANCER THERAPEUTICS

A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma

(2008) Arturo Molina   Annual Review of Medicine

Novel human antibody therapeutics: The age of the Umabs

(2008) Sigrid R. Ruuls et al.   Biotechnology Journal

Fc RIIIa Expression Is Not Increased on Natural Killer Cells Expressing the Fc RIIIa-158V Allotype

(2008) N. Congy-Jolivet et al.   CANCER RESEARCH

Interleukin-15/Interleukin-15R  Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8+ T Cells

(2008) M. Epardaud et al.   CANCER RESEARCH

IL-15 trans-presentation promotes human NK cell development and differentiation in vivo

(2008) Nicholas D. Huntington et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Exon-3-Encoded Domain of IL-15Rα Contributes to IL-15 High-Affinity Binding and Is Crucial for the IL-15 Antagonistic Effect of Soluble IL-15Rα

(2008) Grégory Bouchaud et al.   JOURNAL OF MOLECULAR BIOLOGY

NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma

(2007) Esther Moga et al.   EXPERIMENTAL HEMATOLOGY